

Harvest's *BMAC*[™] (Bone Marrow Aspirate Concentrate) System might do for regenerative medicine what 'PCR' has done for cloning genes and drug discovery...

"Autologous adult stem cells derived from bone marrow offer *profound* potential as therapies—but they are extremely difficult to process outside the human body," says Gary Tureski, President of Harvest Technologies. "Our novel technology is *now* making it possible to harvest and concentrate them easily and rapidly—at the point of care, in about 15 minutes—thereby empowering European clinicians to develop non-surgical approaches for difficult-to-treat diseases *today*."

BONE MARROW ASPIRATE CONCENTRATE (BMAC[™])

Internationally, the first and only product that makes possible the use of a clinically effective quantity of cellular compositions, including a large quantity of adult stem cells, from a small aspirate of autologous bone marrow derived from a patient at the point-of-care in 15 minutes.



The result of three years of research, development and validation at The Center for Blood Research.

Concentrates of autologous adult stem cells derived from bone marrow have been shown in international human clinical studies to be significantly effective in achieving tissue regeneration in vascular, orthopedic and cardiovascular diseases.

There have been 20 published studies comprising 36 sites worldwide involving nearly 1500 patients who have been treated using this approach. However, the processing and concentrating of the bone marrow in all of these studies was complicated and time-consuming, with the majority of the concentration techniques requiring six to 12 hours to prepare. **Until now**, there has not been a commercially available, easy to implement system to produce a quality concentrate. Consequently, the markets for

the BMAC technology are large and diversified. Harvest Technologies is focusing its initial commercialization efforts in Europe to support clinical research for the treatment of *Critical Limb Ischemia* (CLI). In this disease state, a patient is typically left with limb amputation as the

only option at present. A recent pilot study in Europe using the BMAC System for patients with CLI resulted in a 60 percent reduction in major amputation among patients studied. A larger, randomized, controlled study involving CLI patients is planned at several U.S. sites.

What they're saying about Harvest's breakthrough...



Dr. Philippe Hernigou
Henri Mondor Hospital (France)
"Using the BMAC System, autologous bone marrow transplantation for therapeutic purposes is, finally, a very simple procedure."



Dr. Sherwin Kevy
Harvard Medical School
"The patient can serve as his own source of naturally occurring biomaterials for treatment to enhance tissue regeneration."



Mr. Don Freeman
Osteonecrosis Patient
"The BMAC System is a 'changing technology', as it could significantly fast-forward stem cell therapy research. It's a shame it's not available in the U.S."